Selank vs Survodutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Selank
Selank is a synthetic peptide derived from the naturally occurring immunomodulatory peptide tuftsin. Developed in Russia for anxiety and cognitive enhancement.
Full details →Survodutide
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It is being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and obesity. Survodutide's glucagon receptor activation promotes hepatic fat mobilization, making it uniquely suited for liver-related metabolic conditions.
Full details →Side-by-Side Comparison
| Aspect | Selank | Survodutide |
|---|---|---|
| Mechanism | Modulates the expression of brain-derived neurotrophic factor (BDNF) and affects serotonin and norepinephrine systems. Has immunomodulatory and anxiolytic properties. | Survodutide activates both GLP-1 and glucagon receptors. The GLP-1 component provides appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying. The glucagon component drives hepatic fat oxidation, increases energy expenditure, and promotes lipolysis. This dual mechanism is particularly effective for MASH, where hepatic fat accumulation is the core pathology. Unlike tirzepatide (which targets GIP/GLP-1), survodutide targets glucagon/GLP-1 — a different receptor combination optimized for liver and metabolic outcomes. |
| Typical Dosage | Intranasal administration: 250-500mcg 2-3 times daily. Subcutaneous: 250-500mcg daily. | Phase 2 MASH trial: escalated to 2.4 mg, 4.8 mg, or 6.0 mg weekly. Phase 2b obesity trial: up to 6.0 mg weekly. Dose escalation over 16-20 weeks to manage GI tolerability. Final approved dosing not yet established — Phase 3 trials ongoing. |
| Administration | Most commonly administered intranasally for cognitive effects. Can also be injected subcutaneously. | Subcutaneous injection, once weekly. Phase 3 trials use pre-filled pens. Not yet commercially available. Phase 3 results expected 2026-2027. |
| Side Effects | Generally well-tolerated. Some users report mild fatigue or nasal irritation with intranasal use. | Phase 2 data: nausea, vomiting, diarrhea (dose-dependent, generally transient). Reduced appetite. Transient increases in heart rate. The GI side effect profile appears similar to other GLP-1 agonists. |
| Best For |
Key Differences
Unique to Selank:
Unique to Survodutide:
Detailed Analysis
Commonalities
Selank and Survodutide are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose Selank for Cognitive Performance. Choose Survodutide for Weight Loss, Liver Health.
Ready to Learn More?
Looking for trusted sources?